Pharmacometabolomics uncovers key metabolic changes in the first-in-human study of β-lapachone derivative
These metabolic alterations highlight the potential of endogenous metabolites as surrogate markers for identifying novel therapeutic targets and assessing the efficacy of WK0202 in future clinical studies.
Authors
- Ji-Hyun Kang (ORCID: https://orcid.org/0000-0002-4435-6864)
- Joo‐Youn Cho (ORCID: https://orcid.org/0000-0001-9270-8273)
- Eunsol Yang (ORCID: https://orcid.org/0000-0003-2581-349X)
- Woori Chae (ORCID: https://orcid.org/0000-0001-7968-1504)
- Yeonseo Jang (ORCID: https://orcid.org/0009-0008-4245-4605)
- SeungHwan Lee (ORCID: https://orcid.org/0000-0002-1713-9194)
- Yufei Li (ORCID: https://orcid.org/0000-0001-9657-2537)
Institutions
- Seoul National University (KR)
- Cisco Systems (China) (CN)
- Washington University in St. Louis (US)
- Seoul National University Hospital (KR)
- National University College (PR)
Publication Details
- Journal
- Metabolomics
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1007/s11306-025-02332-1
- Citations
- 1
- Primary Topic
- Bioactive Compounds and Antitumor Agents
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- National Research Foundation
- Seoul National University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea